

REMARKS


Claims 13-17 and 19 are pending. Claim 13 stands rejected under 35 U.S.C. § 103(a) over Matter et al., J. Med. Chem. 2002 45:2923 ("Matter"), and all claims stand rejected under 35 U.S.C. § 103(a) over Waer et al., U.S. Patent No. 7,276,506 ("Waer").

The Office again asserts that 2-amino-4-morpholino-6-(4-ethoxyphenyl)pteridine is unpatentable over Matter and Waer, each of which teaches 2-amino-4-morpholino-6-(4-methoxyphenyl)pteridine. Without agreeing with the Office's assertions and in order to expedite prosecution, Applicants have deleted 2-amino-4-morpholino-6-(4-ethoxyphenyl)pteridine from claim 13 and thus from its dependent claims. Applicants reserve the right to pursue the deleted subject matter in one or more continuation applications. As a result of this amendment, this ground for rejection is therefore moot.

Applicants submit that the claims are in condition for allowance, and such action is respectfully requested. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 9/22/2008



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045